AstraZeneca, Daiichi unpack Dato-DXd's overall survival fail ahead of FDA decision dlvr.it/TD3cfM

Boehringer and Bayer's oral meds deliver in early HER-2 mutant lung cancer studies dlvr.it/TD2KTs

MBX aims for $136M IPO to take potential rival to Ascendis' Yorvipath into phase 3 dlvr.it/TD1k6r

Merck, Daiichi repeat early success in small cell lung cancer with updated ADC data dlvr.it/TD1k6j

Tern’s oral GLP-1 shows 5% weight loss at 1 month at highest dose dlvr.it/TD1k6J

GSK's long-acting asthma drug halved attacks in phase 3, backing up blockbuster hopes dlvr.it/TD1k4z

Relay races toward pivotal trial as breast cancer data tee up clash with AstraZeneca's Truqap dlvr.it/TD1LfZ

Lilly-backed Superluminal raises $120M series A to bring membrane receptor drugs into the clinic dlvr.it/TD1Lf0

With $370M debut, Candid Therapeutics is upfront about goal to lead a coming T-cell engager wave dlvr.it/TD1Lcy

AstraZeneca execs 'not worried' after IL-33 drug fails to improve COPD breathing in phase 2 dlvr.it/TCzgly

AstraZeneca outlines AI-enabled TROP2 biomarker strategy for Daiichi ADC after limited lung cancer showing dlvr.it/TCzgkx

FDA concerned Iterum’s urinary tract infection drug could cause antimicrobial resistance dlvr.it/TCwD6t

Psyence pays $500k to acquire fellow psilocybin biotech Clairvoyant and phase 2 AUD asset dlvr.it/TCvrsS

Zenas, Bicara set out to raise $180M+ in separate IPOs to fund autoimmune, cancer prospects dlvr.it/TCvrs6

Chutes & Ladders—BMS vet answers Foghorn's call for CBO dlvr.it/TCvrrX

Connect reduces China workforce, mulls strategy for potential Dupixent rival dlvr.it/TCvSPJ

Crestone's antibiotic cures C. diff infections and prevents recurrence better than vancomycin in phase 2 dlvr.it/TCt7jH

Lykos CEO steps down, the latest move in a string of chaotic changes dlvr.it/TCspz0

Astellas unveils Massachusetts lab that will be shared with biotechs, academia researchers dlvr.it/TCspyV

Gene therapy biotech Medera looks back to SPAC as way to go public dlvr.it/TCspxC